[Effect of combined treatment with dopamine receptor agonists and antagonists of aldosterone on the performance of daily blood pressure monitoring in patients with hypertension and concomitant obesity]

Lik Sprava. 2012 Jan-Mar:(1-2):63-8.
[Article in Ukrainian]

Abstract

In hypertensive patients with concomitant obesity observed decrease in activity of dopaminergic system in conjunction with increased activity of the renin-angiotensin-aldosterone system. Identified changes point to the advisability of appointing this group of patients the dopamine receptor agonist - bromocriptine-KV and antagonist of aldosterone - veroshpiron. As a result of treatment was an increase in dopamine levels in the urine, a decrease of aldosterone in the blood, normalization of the daily blood pressure monitoring.

Publication types

  • English Abstract

MeSH terms

  • Adult
  • Aged
  • Aldosterone / blood
  • Blood Pressure / drug effects*
  • Bromocriptine / therapeutic use*
  • Dopamine / urine
  • Dopamine Agonists / therapeutic use*
  • Drug Therapy, Combination
  • Female
  • Humans
  • Hypertension / complications
  • Hypertension / drug therapy*
  • Hypertension / physiopathology
  • Male
  • Middle Aged
  • Mineralocorticoid Receptor Antagonists / therapeutic use*
  • Obesity / complications
  • Obesity / drug therapy*
  • Obesity / physiopathology
  • Receptors, Dopamine / metabolism
  • Renin-Angiotensin System / drug effects
  • Spironolactone / therapeutic use*

Substances

  • Dopamine Agonists
  • Mineralocorticoid Receptor Antagonists
  • Receptors, Dopamine
  • Spironolactone
  • Bromocriptine
  • Aldosterone
  • Dopamine